Cargando…
Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we
Although hepatocellular carcinoma (HCC) is as prevalent as ever as a cancer-related mortality, and some would even argue that it is increasing, the pattern of its etiologies has been changing. Specifically, the domination of viral hepatitis C virus is being overcome, partly because of the emergence...
Autor principal: | Tsoulfas, Georgios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689805/ https://www.ncbi.nlm.nih.gov/pubmed/31413522 http://dx.doi.org/10.3748/wjg.v25.i29.3842 |
Ejemplares similares
-
Which treatment modality should we choose for advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2010) -
Folate Metabolism in Hepatocellular Carcinoma. What Do We Know So Far?
por: Quevedo-Ocampo, Jaqueline, et al.
Publicado: (2022) -
Maintenance Intravenous Fluids in Children, Should We Change?
por: Al-Lawati, Tawfiq Taki, et al.
Publicado: (2021) -
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
por: Negri, Francesca, et al.
Publicado: (2021) -
The journey continues ... and so we evolve
por: Nayak, Barun Kumar
Publicado: (2008)